A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer

References

• Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer 2000; 36: 1032–7
   PubMed Web of Science ®Google Scholar
• Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: A randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15: 283–9
   PubMed Web of Science ®Google Scholar
• Pinto HA, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am 1991; 5: 667–86
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257–63
   PubMed Web of Science ®Google Scholar
• Guaraldi M, Martoni A, Tononi A, Occhiuzzi L, Caliceti U, Dall‘Olia D, et al. 5-Fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma. Ann Oncol 1991; 2: 379–81
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Shank D, Neuberg D, Taylor IV SG, DeConti RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck. An Eastern Cooperative Oncology Group Trial (PA390). Cancer 1998; 82: 2270–4
   PubMed Web of Science ®Google Scholar
• Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarni JW, Busse PM, et al. Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14: 1672–8
   PubMed Web of Science ®Google Scholar
• Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensly J. Paclitaxel, Cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 1999; 89: 2364–9
   Google Scholar
• Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, et al. Phase II Trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 1325–30
   PubMed Web of Science ®Google Scholar
• Okuno SH, Mailliard JA, Suman VJ, Edmonson JH, Creagan ET, Nair S, et al. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck. Cancer 2002; 94: 2224–31
   PubMed Web of Science ®Google Scholar
• Espinosa, E, Zamora, P, Millá, A, Morales, S, Molina, R, Mira, M, et al. A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 2002;12:1054–9.
   Google Scholar
• Gedlicka C, Formanek M, Selzer E, Burian M, Kornfehl J, Fiebiger W, et al. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology 2002; 63: 145–50
   PubMed Web of Science ®Google Scholar
• Clark JI, Hofmeister C, Choudhury A, Matz G, Collins S, Bastian R, et al. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 2001; 92: 2334–40
   PubMed Web of Science ®Google Scholar
• Hitt R, Castellano D, Hidalgo M, Garcia-Carbonero R, Pena M, Brandariz A, et al. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol 1998; 9: 1347–9
   PubMed Web of Science ®Google Scholar
• Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PHM, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 521–6
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer. J Clin Oncol 2001; 19: 1088–95
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Johnson J, Jiminez U, Gore M, Kosmidis P, Szpirglas H, et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 1998; 16: 1054–9
   PubMed Web of Science ®Google Scholar
• Shin DM, Glisson BS, Khuri FR, Ginsberg L, Lawhorn K, Waun KH, et al. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 1997; 24: 33–7
   Google Scholar
• Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol 1992; 10: 1245–51
   PubMed Web of Science ®Google Scholar
• The Liverpool Head and Neck Oncology Group. A phase III randomised trial of cistplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 1990; 61: 311–5
   PubMedGoogle Scholar
• Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials. Semin Oncol 1994; 21: 311–9
   PubMed Web of Science ®Google Scholar
• Sørensen P, Andersen LJ, Hansen O, Bastholt L. Long-term continuous 5-fluorouracil infusion in patients with advanced head and neck cancer. Acta Oncol 1999; 38: 1043–5
   PubMed Web of Science ®Google Scholar
• Tapazoglou E, Kish J, Ensley J, Al-Sarraf M. The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer. Cancer 1986; 57: 1105–9
   PubMed Web of Science ®Google Scholar
• Gebbia V, Testa A, Valenza R, Zerillo G, Restivo S, Ingria F, et al. A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 1993; 29A(9)1358–9
   PubMed Web of Science ®Google Scholar
• Testolin A, Recher G, Cristoferi V, Gasparini G. Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. A phase II study. Invest New Drugs 1994; 12: 231–4
   PubMed Web of Science ®Google Scholar
• Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425–32
   PubMed Web of Science ®Google Scholar
• WHO. Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva 1979
   Google Scholar